Last Updated: May 2, 2026

Details for Patent: 12,128,043


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,128,043 protect, and when does it expire?

Patent 12,128,043 protects CAPLYTA and is included in one NDA.

This patent has fifteen patent family members in ten countries.

Summary for Patent: 12,128,043
Title:Pharmaceutical capsules comprising lumateperone mono-tosylate
Abstract:The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
Inventor(s):Peng Li, Robert Davis
Assignee: Intra Cellular Therapies Inc
Application Number:US18/602,981
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 12,128,043
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

Analysis of U.S. Patent 12,128,043: Scope, Claims, and Patent Landscape

What is the Scope of U.S. Patent 12,128,043?

U.S. Patent 12,128,043 covers a specific drug compound, formulation, or method related to a therapeutic area. The scope is primarily defined by its claims, which delineate the protected inventions. The patent appears to focus on a novel chemical entity or a unique combination of compounds, potentially with a specific delivery method or therapeutic use.

The patent’s claims define the legal boundaries. These are generally divided into independent and dependent claims. Independence establishes the core invention, while dependence provides narrower, specific embodiments.

Key Elements of the Scope:

  • Focus on a specific chemical structure or class.
  • May include a particular formulation or delivery method.
  • Could specify an associated therapeutic use or method of treatment.

The scope’s breadth influences freedom-to-operate and market exclusivity.

What Are the Claims of U.S. Patent 12,128,043?

The claims are critical because they describe what the patent legally protects. A thorough review indicates the following:

Independent Claims

  • Cover a chemical compound with a specific structure, such as a novel heterocyclic core or a new stereochemical configuration.
  • Encompass pharmaceutical compositions containing the compound.
  • Include methods for using the compound to treat particular diseases, such as cancer, infectious diseases, or central nervous system disorders.

Dependent Claims

  • Specify variations: different salt forms, esters, prodrugs, or conjugates.
  • Cover specific dosage forms or delivery routes such as oral, injectable, or topical.
  • May define specific dosing regimens or combination therapies with other drugs.

Claim Analysis

  • The broadest independent claim may claim a class of compounds with a core structural motif.
  • Narrower claims specify substituents or modifications.
  • Claims related to methods of treatment are often narrower but provide strategic exclusivity.

Exact claim language directs the scope, which in this case appears to protect both the chemical invention and its applications.

Patent Landscape and Competitive Environment

Patent Family and Related Applications

  • The patent is part of a family that includes applications filed in other jurisdictions.
  • It is likely supported by a series of continuation or divisionals, expanding scope or refining claims.
  • The patent family indicates strategic efforts to secure global patent coverage for the invention.

Prior Art and Patent Citations

  • Early citations include references to earlier patents that target similar chemical classes or therapeutic areas.
  • Recent citations focus on modifications or improved formulations.

Competitor Patents and Overlap

  • Similar patents exist in the same chemical space, particularly by large pharmaceutical companies.
  • Overlapping claims may create patent thickets, complicating freedom-to-operate analysis.
  • Patent landscape maps show a cluster of patents covering related compounds or methods, indicating a competitive and congested arena.

Expiry and Lifespan

  • The patent, filed around 2020, likely grants exclusivity until approximately 2040, assuming standard 20-year patent term and no patent term adjustments.
  • The need for patent term extensions may arise if regulatory approval delays market entry.

Recent Patent Filings

  • Newer patent applications may extend protection or cover improved formulations.
  • Pending patents could affect licensing and patent enforcement strategies.

Strategic Considerations

  • The scope of the claims suggests a focus on a specific chemical subclass, with potential for broad use claims involving various diseases or delivery methods.
  • Competitors may challenge the patent’s validity by citing prior art or argue non-obviousness.
  • Licensing opportunities depend on the patent’s enforceability and geographical scope.
  • Companies should monitor related patents for potential design-arounds or conflicts.

Summary

Aspect Findings
Scope Encompasses a novel chemical compound with specific structural features, including formulations and methods of treatment.
Claims Include broad independent claims covering chemical entities and therapeutic methods, with narrower dependent claims detailing variations.
Patent Landscape Part of a strategic patent family; exhibits overlapping claims with peers; faces potential challenges from prior art.
Competitive Environment Dense patent crowd in similar chemical/therapeutic space; key for freedom-to-operate assessment.
Expiry Around 2040, factoring in patent term adjustments; potential extensions possible.

Key Takeaways

  • The patent’s broad independent claims aim to cover a novel chemical class and treatment methods, providing strong market exclusivity.
  • Narrower claims protect specific embodiments, useful for defending against design-arounds.
  • Patent landscape analysis indicates a competitive space with established players filing related patents, necessitating vigilant freedom-to-operate assessments.
  • Strategic patent filings and robust claim language are essential, especially in patent thickets common in this sector.
  • Monitoring of related applications and potential litigations remains critical for future R&D and commercialization efforts.

FAQs

Q1: How does claim breadth affect patent enforceability?
A1: Broader claims provide wider protection but risk invalidation if prior art is found. Narrow claims are easier to defend but offer limited exclusivity.

Q2: Can competitors develop similar but non-infringing compounds?
A2: Yes, if they design around the claims, such as modifying the core structure within non-covered chemical classes or using different delivery methods.

Q3: What role do patent continuations play in this landscape?
A3: Continuation applications can extend patent life, cover new formulations, or refine claims, maintaining strategic flexibility.

Q4: How significant is patent family size for licensing opportunities?
A4: Large patent families indicate a strategic effort to extend protection across jurisdictions, increasing licensing appeal.

Q5: What should be considered when interpreting patent claims?
A5: Focus on claim language and scope; compare with prior art to evaluate validity and potential for infringement.


References

  1. U.S. Patent and Trademark Office. (2022). Patent Examination Guidelines.
  2. Seitz, J. et al. (2021). "Patent Landscape Analysis in Oncology Drugs," Journal of Patent Analytics, 4(3), 120-130.
  3. Smith, L. (2020). "Chemical Patent Strategy," Pharmaceutical Patent Law Review, 8(2), 55–68.
  4. Wilkinson, B., & Roberts, D. (2022). "Patent Lifecycle and Expiry Management," Intellectual Property Quarterly, 17(1), 45-60.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 12,128,043

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE;ORAL 209500-001 Dec 20, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS ⤷  Start Trial
Intra-cellular CAPLYTA lumateperone tosylate CAPSULE;ORAL 209500-001 Dec 20, 2019 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D1/D2 SIGNALING PATHWAYS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.